El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

Viking Therapeutics (NASDAQ: VKTX) didn't exactly capture investors' hearts in the final month of 2024. In mid-December, ...

This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...

It's been an excellent year for Viking Therapeutics ( VKTX 4.30%), a mid-cap biotech company. Thanks to impressive mid-stage ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...